Involvement of miR-30a-5p and miR-30d in Endothelial to Mesenchymal Transition and Early Osteogenic Commitment under Inflammatory Stress in HUVEC

Biomolecules. 2021 Feb 5;11(2):226. doi: 10.3390/biom11020226.

Abstract

The endothelial to mesenchymal transition (End-MT) can be associated with vascular calcification, by providing mesengenic progenitors. In this study, we investigated a link between End-MT and the osteogenic process and explored the involvement of miR-30a-5p and miR-30d as potential regulators of these processes. End-MT was induced in Human Umbilical Vein Endothelial Cells (HUVEC) through transforming growth factor-β1 (TGF-β1), TGFβ-3 and tumor necrosis factor-α (TNF-α), for 24 h and 6 days. End-MT mediators, mesenchymal and osteo/chondrogenic markers were analyzed through Real-Time PCR, immunofluorescence, flow cytometry and Western Blot. miR-30a-5p and miR-30d over-expression was carried out in HUVEC to explore their effects on End-MT and osteogenic differentiation. HUVEC at 24 h and 6 days gained mesenchymal morphology markers, including matrix metalloproteinase 9 (MMP-9), SLUG, VIMENTIN and α-smooth muscle actin (α-SMA), and a significant migratory potential, notably with TNF-α. After 6 days, the osteo/chondrogenic markers runt-related transcription factor 2 (RUNX-2) and SRY box transcription factor 9 (SOX-9) were upregulated. At this time point, miR-30a-5p and miR-30d decreased. Over-expression of miR-30a-5p and miR-30d affected End-MT mediators and the osteogenic potency in HUVEC, by reducing SLUG, VIMENTIN and RUNX-2. Our data suggest that End-MT represents a key link between inflammation and vascular calcification. Further, miR-30a-5p and miR-30d can regulate both the End-MT and the osteogenic processes, prompting future studies for exploring their potential use as therapeutic targets or biomarkers in vascular diseases.

Keywords: atherosclerosis; calcification; endothelial to mesenchymal transition; inflammation; micro-RNA; osteogenic differentiation; vascular injury.

MeSH terms

  • Actins / genetics
  • Actins / metabolism
  • Cell Differentiation / drug effects
  • Cell Movement / drug effects
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Core Binding Factor Alpha 1 Subunit / metabolism
  • Gene Expression Regulation / drug effects*
  • Human Umbilical Vein Endothelial Cells / cytology
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Osteoblasts / cytology
  • Osteoblasts / drug effects
  • Osteoblasts / metabolism
  • Osteogenesis / drug effects*
  • Osteogenesis / genetics
  • SOX9 Transcription Factor / genetics
  • SOX9 Transcription Factor / metabolism
  • Signal Transduction
  • Snail Family Transcription Factors / genetics
  • Snail Family Transcription Factors / metabolism
  • Transforming Growth Factor beta1 / pharmacology*
  • Transforming Growth Factor beta3 / pharmacology*
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Vimentin / genetics
  • Vimentin / metabolism

Substances

  • ACTA2 protein, human
  • Actins
  • Core Binding Factor Alpha 1 Subunit
  • MIRN30b microRNA, human
  • MicroRNAs
  • RUNX2 protein, human
  • SNAI1 protein, human
  • SOX9 Transcription Factor
  • SOX9 protein, human
  • Snail Family Transcription Factors
  • TGFB1 protein, human
  • TGFB3 protein, human
  • Transforming Growth Factor beta1
  • Transforming Growth Factor beta3
  • Tumor Necrosis Factor-alpha
  • VIM protein, human
  • Vimentin
  • MMP9 protein, human
  • Matrix Metalloproteinase 9